Candesartan for Daily Headaches with Migrainous Features

Efficacy and Evidence

The American Academy of Neurology recommends candesartan as a first-line medication for the prevention of daily headaches with migrainous features at a dose of 16 mg orally per day, with a strong evidence level 1, 2
Candesartan is recognized as a first-line preventive treatment for migraine in multiple clinical guidelines, alongside beta blockers and topiramate, with a high strength of evidence 1, 3, 4
The standard therapeutic dose is 16 mg orally once daily, with the option to increase to 32 mg daily in patients requiring additional efficacy, as recommended by clinical guidelines 2
Candesartan is particularly beneficial for patients who experience migraines on ≥2 days per month despite optimized acute treatment, with a moderate to high strength of evidence 1, 2

The treatment protocol for candesartan involves beginning with 16 mg oral candesartan once daily, with a maintenance period of at least 2-3 months before determining efficacy, as recommended by clinical guidelines 2
If effective, treatment should be continued for 6-12 months before considering discontinuation, with regular monitoring of efficacy and side effects 2
For patients with inadequate response, dosage may be increased to 32 mg daily, with close monitoring of side effects and efficacy 2

Candesartan has the advantage of once-daily dosing, which improves treatment adherence, with a high strength of evidence 2
Unlike beta blockers and tricyclic antidepressants, candesartan does not cause weight gain, with a moderate strength of evidence 5
Unlike topiramate, candesartan does not cause cognitive slowing or depression, with a moderate strength of evidence 5

The primary contraindication for candesartan is co-administration with aliskiren, with a high strength of evidence 1, 2
Candesartan is contraindicated during pregnancy due to potential fetal harm, with a high strength of evidence 4, 2
Candesartan should be used with caution in patients with renal impairment, with a moderate strength of evidence 2

Efficacy of candesartan should be assessed after 2-3 months of consistent use, with a moderate strength of evidence 2
Success is measured by percentage reduction in monthly migraine days or headache intensity, with a high strength of evidence 2
If ineffective after an adequate trial, consider switching to another first-line agent such as a beta blocker (propranolol, metoprolol) or topiramate, with a moderate to high strength of evidence 1, 2

If candesartan fails, consider second-line medications such as flunarizine, amitriptyline, or sodium valproate (the latter contraindicated in women of childbearing potential), with a moderate strength of evidence 1, 4
Third-line options include CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab), with a high strength of evidence 1, 3
Non-pharmacological approaches like neuromodulatory devices, biobehavioral therapy, and acupuncture can be considered as adjuncts, with a moderate strength of evidence 1